This is a preview of subscription content, log in via an institution to check access.
Notes
see Reactions 1553 p4; 803124342
Reference
Health Canada. Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis). Internet Document : 16 May 2016. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-2-eng.php
Rights and permissions
About this article
Cite this article
SGLT2 inhibitors increase the risk of diabetic ketoacidosis. Reactions Weekly 1603, 9 (2016). https://doi.org/10.1007/s40278-016-17808-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-17808-1